Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
Author:
Publisher
Elsevier BV
Subject
Clinical Neurology,Neurology
Reference44 articles.
1. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders;Wingerchuk;Neurology,2015
2. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica;Collongues;Ther Adv Neurol Disord,2016
3. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability;Zéphir;J Neurol,2015
4. Efficacy of rituximab in refractory neuromyelitis optica;Collongues;Mult Scler,2016
5. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients;van Vollenhoven;Ann Rheum Dis,2013
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations;Revue Neurologique;2024-07
2. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder;Multiple Sclerosis and Related Disorders;2024-06
3. Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease;Cureus;2024-05-09
4. Dental Adverse Effects of Anti-CD20 Therapies;Neurology and Therapy;2024-04-26
5. Neuromyelitis Optica and Immune Thrombocytopenic Purpura Treated With Rituximab in a Patient With Combined Neurologic and Hematologic Disorder: A Case Report;Cureus;2024-04-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3